Abixa Dosage/Direction for Use

Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Therapy should only be started if a caregiver is available who will regularly monitor drug intake by the patient. Diagnosis should be made according to current guidelines.
The tablets can be taken with or without food.
Adults: Maximum Daily Dose: 20 mg/day. In order to reduce the risk of side effects, the maintenance dose is achieved by upward titration 5 mg/week over the first 3 weeks as follows: Treatment should be started with 5 mg daily (½ tab in the morning) during the 1st week. In the 2nd week, 10 mg/day (½ tab twice a day) and in the 3rd week 15 mg/day is recommended (1 tab in the morning and ½ tab in the afternoon). From the 4th week on, treatment can be continued with the recommended maintenance dose of 20 mg/day (1 tab twice a day).
Elderly >65 years: Recommended Dose: 20 mg/day (10 mg twice a day) as previously described.
Children and Adolescents <18 years: The safety and efficacy of memantine in children and adolescents have not been established.
Renal Impairment: In patients with normal to mildly impaired renal function (serum creatinine levels of up to 130 micromole/L) no dose reduction is needed. In patients with moderate renal impairment (CrCl 40-60 mL/min/1.73 m²) daily dose should be reduced to 10 mg/day. No data are available for patients with severely reduced kidney function (see Precautions and Pharmacokinetics under Actions).
Hepatic Impairment: There are no data on the use of memantine in patients with hepatic impairment (see Pharmacokinetics under Actions).